In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...

Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

Biogen's hopes were for sales of around $18 billion per year from Aduhelm, says the document, without consideration of the impact that could have on the US healthcare system.

A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...

In the fourth quarter of 2021, for example, Aduhelm could only muster $1 million in sales. Since then, prospects for the biologic didn’t appreciably improve. The drug’s manufacturer Biogen ...

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...

Biogen said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. Apple is working on features designed to detect depression ...

Investors knocked Biogen stock down by more than 10% early Wednesday after the US Centers for Medicare and Medicaid Services set a limit on its coverage of Aduhelm, the company's drug to treat ...